APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angiotensin II Type 1 Receptor (AT1R) Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchAngiotensin II Type 1 Receptor (AT1R) Antagonists Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Angiotensin II Type 1 Receptor (AT1R) Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Angiotensin II Type 1 Receptor (AT1R) Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Angiotensin II Type 1 Receptor (AT1R) Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiotensin II Type 1 Receptor (AT1R) Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiotensin II Type 1 Receptor (AT1R) Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Angiotensin II Type 1 Receptor (AT1R) Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Angiotensin II Type 1 Receptor (AT1R) Antagonists market include Takeda Pharmaceutical Co., Ltd., Shenzhen Salubris Pharmaceuticals Co., Ltd., Sanofi SA, Novartis, Merck, AbbVie, Inc., Cosette Pharmaceuticals, Inc. and Aurobindo Pharma Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiotensin II Type 1 Receptor (AT1R) Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiotensin II Type 1 Receptor (AT1R) Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiotensin II Type 1 Receptor (AT1R) Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiotensin II Type 1 Receptor (AT1R) Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiotensin II Type 1 Receptor (AT1R) Antagonists Segment by Company

Takeda Pharmaceutical Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Sanofi SA

Novartis

Merck

AbbVie, Inc.

Cosette Pharmaceuticals, Inc.

Aurobindo Pharma Ltd.

Angiotensin II Type 1 Receptor (AT1R) Antagonists Segment by Type

5mg

10mg

20mg

50mg

80mg

100mg

150mg

400mg

Angiotensin II Type 1 Receptor (AT1R) Antagonists Segment by Application

Hospital

Clinic

Others

Angiotensin II Type 1 Receptor (AT1R) Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Angiotensin II Type 1 Receptor (AT1R) Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Angiotensin II Type 1 Receptor (AT1R) Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Angiotensin II Type 1 Receptor (AT1R) Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze Angiotensin II Type 1 Receptor (AT1R) Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin II Type 1 Receptor (AT1R) Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiotensin II Type 1 Receptor (AT1R) Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin II Type 1 Receptor (AT1R) Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiotensin II Type 1 Receptor (AT1R) Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Angiotensin II Type 1 Receptor (AT1R) Antagonists industry.

Chapter 3: Detailed analysis of Angiotensin II Type 1 Receptor (AT1R) Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Angiotensin II Type 1 Receptor (AT1R) Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Angiotensin II Type 1 Receptor (AT1R) Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Trends Table 2. Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Drivers Table 3. Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Opportunities and Challenges Table 4. Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Restraints Table 5. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Revenue Share by Company (2021-2026) Table 7. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company, Product Type & Application Table 13. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5mg Table 18. Significant Companies of 10mg Table 19. Significant Companies of 20mg Table 20. Significant Companies of 50mg Table 21. Significant Companies of 80mg Table 22. Significant Companies of 100mg Table 23. Significant Companies of 150mg Table 24. Significant Companies of 400mg Table 25. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Type (2021-2026) & (K Units) Table 27. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Type (2027-2032) & (K Units) Table 28. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Type (2021-2026) Table 29. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Type (2027-2032) Table 30. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type (2021-2026) Table 34. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Hospital Table 36. Significant Companies of Clinic Table 37. Significant Companies of Others Table 38. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Application (2021-2026) & (K Units) Table 40. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Application (2027-2032) & (K Units) Table 41. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Application (2021-2026) Table 42. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Application (2027-2032) Table 43. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application (2021-2026) Table 47. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application (2027-2032) Table 48. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region (2021-2026) & (K Units) Table 50. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Market Share by Region (2021-2026) Table 51. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region (2027-2032) & (K Units) Table 52. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Market Share by Region (2027-2032) Table 53. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Region (2021-2026) Table 56. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Region (2027-2032) Table 58. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Country (2021-2026) & (K Units) Table 63. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Market Share by Country (2021-2026) Table 64. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Country (2027-2032) & (K Units) Table 65. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Market Share by Country (2027-2032) Table 66. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Market Share by Country (2021-2026) Table 68. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Market Share by Country (2027-2032) Table 70. Takeda Pharmaceutical Co., Ltd. Company Information Table 71. Takeda Pharmaceutical Co., Ltd. Business Overview Table 72. Takeda Pharmaceutical Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Takeda Pharmaceutical Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 74. Takeda Pharmaceutical Co., Ltd. Recent Development Table 75. Shenzhen Salubris Pharmaceuticals Co., Ltd. Company Information Table 76. Shenzhen Salubris Pharmaceuticals Co., Ltd. Business Overview Table 77. Shenzhen Salubris Pharmaceuticals Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Shenzhen Salubris Pharmaceuticals Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 79. Shenzhen Salubris Pharmaceuticals Co., Ltd. Recent Development Table 80. Sanofi SA Company Information Table 81. Sanofi SA Business Overview Table 82. Sanofi SA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Sanofi SA Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 84. Sanofi SA Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Novartis Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 89. Novartis Recent Development Table 90. Merck Company Information Table 91. Merck Business Overview Table 92. Merck Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Merck Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 94. Merck Recent Development Table 95. AbbVie, Inc. Company Information Table 96. AbbVie, Inc. Business Overview Table 97. AbbVie, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. AbbVie, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 99. AbbVie, Inc. Recent Development Table 100. Cosette Pharmaceuticals, Inc. Company Information Table 101. Cosette Pharmaceuticals, Inc. Business Overview Table 102. Cosette Pharmaceuticals, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Cosette Pharmaceuticals, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 104. Cosette Pharmaceuticals, Inc. Recent Development Table 105. Aurobindo Pharma Ltd. Company Information Table 106. Aurobindo Pharma Ltd. Business Overview Table 107. Aurobindo Pharma Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Aurobindo Pharma Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio Table 109. Aurobindo Pharma Ltd. Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Angiotensin II Type 1 Receptor (AT1R) Antagonists Distributors List Table 113. Angiotensin II Type 1 Receptor (AT1R) Antagonists Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Image Figure 2. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales (2021-2032) & (K Units) Figure 5. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5mg Image Figure 10. 10mg Image Figure 11. 20mg Image Figure 12. 50mg Image Figure 13. 80mg Image Figure 14. 100mg Image Figure 15. 150mg Image Figure 16. 400mg Image Figure 17. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Type (2021-2032) Figure 20. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type (2021-2032) Figure 23. Hospital Image Figure 24. Clinic Image Figure 25. Others Image Figure 26. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Application (2021-2032) Figure 29. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application (2021-2032) Figure 32. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032) & (US$ Million) Figure 37. North America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032) & (US$ Million) Figure 43. South America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Angiotensin II Type 1 Receptor (AT1R) Antagonists Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • 5mg
  • 10mg
  • 20mg
  • 50mg
  • 80mg
  • 100mg
  • 150mg
  • 400mg
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceutical Co., Ltd.
  • Shenzhen Salubris Pharmaceuticals Co., Ltd.
  • Sanofi SA
  • Novartis
  • Merck
  • AbbVie, Inc.
  • Cosette Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Dynamics
  1. 2.1 Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Trends
  2. 2.2 Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Drivers
  3. 2.3 Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Opportunities and Challenges
  4. 2.4 Angiotensin II Type 1 Receptor (AT1R) Antagonists Industry Restraints
3 Angiotensin II Type 1 Receptor (AT1R) Antagonists Market by Company
  1. 3.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Ranking (2024-2026)
  6. 3.6 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Product Type and Application
  8. 3.8 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Angiotensin II Type 1 Receptor (AT1R) Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Angiotensin II Type 1 Receptor (AT1R) Antagonists Market by Type
  1. 4.1 Angiotensin II Type 1 Receptor (AT1R) Antagonists Type Introduction
  2. 4.1.1 5mg
  3. 4.1.2 10mg
  4. 4.1.3 20mg
  5. 4.1.4 50mg
  6. 4.1.5 80mg
  7. 4.1.6 100mg
  8. 4.1.7 150mg
  9. 4.1.8 400mg
  10. 4.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Type
  11. 4.2.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Type
  15. 4.3.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Type (2021-2032)
  17. 4.3.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type (2021-2032)
5 Angiotensin II Type 1 Receptor (AT1R) Antagonists Market by Application
  1. 5.1 Angiotensin II Type 1 Receptor (AT1R) Antagonists Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Application
  6. 5.2.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Application
  10. 5.3.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Application (2021-2032)
  12. 5.3.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application (2021-2032)
6 Angiotensin II Type 1 Receptor (AT1R) Antagonists Regional Sales and Value Analysis
  1. 6.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Region (2027-2032)
  5. 6.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Country, 2025 VS 2032
7 Angiotensin II Type 1 Receptor (AT1R) Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales by Country (2027-2032)
  6. 7.4 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Co., Ltd.
  2. 8.1.1 Takeda Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Takeda Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Takeda Pharmaceutical Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Shenzhen Salubris Pharmaceuticals Co., Ltd.
  8. 8.2.1 Shenzhen Salubris Pharmaceuticals Co., Ltd. Company Information
  9. 8.2.2 Shenzhen Salubris Pharmaceuticals Co., Ltd. Business Overview
  10. 8.2.3 Shenzhen Salubris Pharmaceuticals Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shenzhen Salubris Pharmaceuticals Co., Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  12. 8.2.5 Shenzhen Salubris Pharmaceuticals Co., Ltd. Recent Developments
  13. 8.3 Sanofi SA
  14. 8.3.1 Sanofi SA Company Information
  15. 8.3.2 Sanofi SA Business Overview
  16. 8.3.3 Sanofi SA Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi SA Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  18. 8.3.5 Sanofi SA Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 AbbVie, Inc.
  32. 8.6.1 AbbVie, Inc. Company Information
  33. 8.6.2 AbbVie, Inc. Business Overview
  34. 8.6.3 AbbVie, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  36. 8.6.5 AbbVie, Inc. Recent Developments
  37. 8.7 Cosette Pharmaceuticals, Inc.
  38. 8.7.1 Cosette Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Cosette Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Cosette Pharmaceuticals, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cosette Pharmaceuticals, Inc. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  42. 8.7.5 Cosette Pharmaceuticals, Inc. Recent Developments
  43. 8.8 Aurobindo Pharma Ltd.
  44. 8.8.1 Aurobindo Pharma Ltd. Company Information
  45. 8.8.2 Aurobindo Pharma Ltd. Business Overview
  46. 8.8.3 Aurobindo Pharma Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Aurobindo Pharma Ltd. Angiotensin II Type 1 Receptor (AT1R) Antagonists Product Portfolio
  48. 8.8.5 Aurobindo Pharma Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiotensin II Type 1 Receptor (AT1R) Antagonists Value Chain Analysis
  2. 9.1.1 Angiotensin II Type 1 Receptor (AT1R) Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Mode & Process
  6. 9.2 Angiotensin II Type 1 Receptor (AT1R) Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiotensin II Type 1 Receptor (AT1R) Antagonists Distributors
  9. 9.2.3 Angiotensin II Type 1 Receptor (AT1R) Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst